Joseph Stringer
Stock Analyst at Needham
(4.59)
# 206
Out of 5,182 analysts
304
Total ratings
50%
Success rate
38.1%
Average return
Main Sectors:
Stocks Rated by Joseph Stringer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Downgrades: Hold | n/a | $40.95 | - | 22 | Mar 31, 2026 | |
| BIOA BioAge Labs | Initiates: Buy | $50 | $18.06 | +176.85% | 1 | Mar 27, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $103 → $105 | $72.23 | +45.37% | 27 | Mar 25, 2026 | |
| STOK Stoke Therapeutics | Maintains: Buy | $35 → $40 | $33.71 | +18.66% | 25 | Mar 17, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $139 → $130 | $85.20 | +52.58% | 31 | Mar 17, 2026 | |
| VIR Vir Biotechnology | Maintains: Buy | $14 → $18 | $10.64 | +69.17% | 20 | Feb 24, 2026 | |
| GILD Gilead Sciences | Reiterates: Buy | $170 | $127.75 | +33.07% | 11 | Feb 23, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $529 → $510 | $308.51 | +65.31% | 25 | Feb 12, 2026 | |
| PCVX Vaxcyte | Maintains: Buy | $90 → $110 | $59.72 | +84.19% | 18 | Jan 7, 2026 | |
| MRNA Moderna | Reiterates: Hold | n/a | $48.70 | - | 9 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 | $11.59 | +141.59% | 52 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $11 | $6.10 | +80.33% | 19 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $426.01 | - | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $1.69 | - | 13 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $10 | $1.21 | +726.45% | 17 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $37 | $22.30 | +65.92% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $18 | $16.81 | +7.08% | 2 | Aug 24, 2021 |
Apellis Pharmaceuticals
Mar 31, 2026
Downgrades: Hold
Price Target: n/a
Current: $40.95
Upside: -
BioAge Labs
Mar 27, 2026
Initiates: Buy
Price Target: $50
Current: $18.06
Upside: +176.85%
Ionis Pharmaceuticals
Mar 25, 2026
Maintains: Buy
Price Target: $103 → $105
Current: $72.23
Upside: +45.37%
Stoke Therapeutics
Mar 17, 2026
Maintains: Buy
Price Target: $35 → $40
Current: $33.71
Upside: +18.66%
Rhythm Pharmaceuticals
Mar 17, 2026
Maintains: Buy
Price Target: $139 → $130
Current: $85.20
Upside: +52.58%
Vir Biotechnology
Feb 24, 2026
Maintains: Buy
Price Target: $14 → $18
Current: $10.64
Upside: +69.17%
Gilead Sciences
Feb 23, 2026
Reiterates: Buy
Price Target: $170
Current: $127.75
Upside: +33.07%
Alnylam Pharmaceuticals
Feb 12, 2026
Maintains: Buy
Price Target: $529 → $510
Current: $308.51
Upside: +65.31%
Vaxcyte
Jan 7, 2026
Maintains: Buy
Price Target: $90 → $110
Current: $59.72
Upside: +84.19%
Moderna
Oct 20, 2025
Reiterates: Hold
Price Target: n/a
Current: $48.70
Upside: -
Jun 6, 2025
Maintains: Buy
Price Target: $28
Current: $11.59
Upside: +141.59%
May 13, 2025
Maintains: Buy
Price Target: $16 → $11
Current: $6.10
Upside: +80.33%
May 6, 2025
Reiterates: Hold
Price Target: n/a
Current: $426.01
Upside: -
Mar 7, 2025
Reiterates: Hold
Price Target: n/a
Current: $1.69
Upside: -
Mar 4, 2025
Downgrades: Hold
Price Target: $10
Current: $1.21
Upside: +726.45%
Jan 24, 2024
Upgrades: Buy
Price Target: $37
Current: $22.30
Upside: +65.92%
Aug 24, 2021
Maintains: Buy
Price Target: $32 → $18
Current: $16.81
Upside: +7.08%